SK Bioscience Wins More Funding for Vaccine Trials
25 May, 2021
SK Bioscience features secured W200 billion in funding for coronavirus vaccine trials from the Coalition for Epidemic Preparedness Innovations, a worldwide partnership (US$1=W1,127).
The funding is for third-phase trials of a COVID-19 vaccine currently under production. SK Bioscience said Monday the amount of money will be applied to test GBP510, a vaccine it really is developing with the University of Washington.
CEPI currently gave SK Bioscience funding for the first- and second-phase trials, bringing the full total to US$210 million.
GBP510 is a "recombinant health proteins nanoparticle" vaccine, like Novavax, and SK programs to start development in the first half of next season.
CEPI was setup by the Wellcome Trust, Costs and Melinda Gates Basis and the Globe Economic Forum. It gets its funding both from governments and specific donors.
Source:
TAG(s):